The connection between high cholesterol and risk of stroke is questioned.
Is Avandia contributing to bone breakage? And more bad news for the GSK diabetes treatment…two healthcare providers drop the medication from their formularies. For switcheroos, it appears that most doctors are leaning toward Januvia or Byetta.
Novartis has plans for 4 more cancer drugs.
Certain lymphoma drugs may be derailed based on this Medicare decision.
Teva‘s Copaxone may actually cut the risk of developing MS.
An interesting perspective from Derek Lowe on why it’s not all bad that companies developing competing drugs in the same class.
An update on the status of eDetailing.
Here’s a fascinating finding – does body temperature (specifically, a fever) unlock the effects of autism??